Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

BACKGROUND: Widespread implementation of immune checkpoint inhibitors (ICI) and targeted therapies for metastatic melanoma has led to a decline in melanoma-related mortality but increased healthcare costs. We aimed to determine how healthcare utilization varied by systemic, non-adjuvant melanoma tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Mollie F, Betancourt, Nicolas J, Pineda, Alain, Maloney, Nolan J, Nguyen, Kevin A, Reddy, Sunil A, Hall, Evan T, Swetter, Susan M, Zaba, Lisa C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020812/
https://www.ncbi.nlm.nih.gov/pubmed/36302223
http://dx.doi.org/10.1093/oncolo/oyac219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020812/
https://www.ncbi.nlm.nih.gov/pubmed/36302223
http://dx.doi.org/10.1093/oncolo/oyac219

Ejemplares similares